A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
Primary Purpose
Methamphetamine Addiction
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
modafinil
Sponsored by
About this trial
This is an interventional treatment trial for Methamphetamine Addiction focused on measuring amphetamine, methamphetamine, addition, treatment study, drug use, modafinil
Eligibility Criteria
Inclusion Criteria:
- Age between 18 and 50 years
- Patient is agreeable to conditions of study and signs consent form
- Fluency in English
Contact site for additional information.
Sites / Locations
- CPMC - St. Luke's Hospital ~ 7th Floor/ Addiction Pharmacology Research Lab
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
modafinil
Arm Description
Outcomes
Primary Outcome Measures
MA (-) urine samples
Secondary Outcome Measures
Full Information
NCT ID
NCT00538655
First Posted
October 2, 2007
Last Updated
May 30, 2013
Sponsor
California Pacific Medical Center Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT00538655
Brief Title
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
Official Title
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
California Pacific Medical Center Research Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients treated for methamphetamine dependence have high rates of relapse, and no pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d, l-2-[(diphenylmethyl) sulfinyl] acetamide) is a novel wake- and vigilance- promoting agent that is chemically and pharmacologically dissimilar to CNS stimulants such as the amphetamines, methylphenidate, and pemoline. It is well tolerated and has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive function, has been shown to reduce cocaine use in dependent users, and is safe when co-administered with intravenous methamphetamine. We will conduct a pilot, open-label clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for methamphetamine dependence.
Specific Aims:
Determine the safety of modafinil in the treatment of methamphetamine dependence.
Determine the efficacy of modafinil in the treatment of methamphetamine dependence.
Assess the effect of modafinil on cognitive function in methamphetamine users.
Assess the effect of modafinil on methamphetamine withdrawal symptoms.
Compare the validity of a cellular telephone-based reporting system for assessing medication regimen adherence to conventional electronic medication monitoring.
Hypotheses:
Modafinil will be as safe and well tolerated as placebo in a comparison group from another study.
Subjects given modafinil will use less methamphetamine than subjects given placebo.
Subjects given modafinil with demonstrate improvements in cognitive function when compared to subjects given placebo.
Subjects given modafinil will have reduced withdrawal symptoms when compared to subjects given placebo.
Adherence will be recorded more accurately by cellular telephone than by conventional electronic medication monitoring.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Methamphetamine Addiction
Keywords
amphetamine, methamphetamine, addition, treatment study, drug use, modafinil
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
modafinil
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
modafinil
Other Intervention Name(s)
Provigil
Intervention Description
400mg vs. 200mg (PO) daily
Primary Outcome Measure Information:
Title
MA (-) urine samples
Time Frame
multiple
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 18 and 50 years
Patient is agreeable to conditions of study and signs consent form
Fluency in English
Contact site for additional information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gantt Galloway, Pharm D.
Organizational Affiliation
California Pacific Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
CPMC - St. Luke's Hospital ~ 7th Floor/ Addiction Pharmacology Research Lab
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
We'll reach out to this number within 24 hrs